Advertisement

Topics

Latest "Oxford Therapeutics Consulting Limited" News Stories

16:44 EST 20th November 2018 | BioPortfolio

Here are the most relevant search results for "Oxford Therapeutics Consulting Limited" found in our extensive news archives from over 250 global news sources.

More Information about Oxford Therapeutics Consulting Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oxford Therapeutics Consulting Limited for you to read. Along with our medical data and news we also list Oxford Therapeutics Consulting Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oxford Therapeutics Consulting Limited Companies for you to search.

Showing "Oxford Therapeutics Consulting Limited" News Articles 1–25 of 9,900+

Relevant

Oxford University Press to publish Antibody Therapeutics

(Oxford University Press USA) Oxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.


Forma Therapeutics, University of Oxford partner to advance DUB inhibitors development

Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.

Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets

Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised ... The post Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets appeared first on Labiotech.eu.


Therapeutics and collaboration in the spotlight at Technology Showcase

This year’s Technology Showcase, held on 13 June at Oxford’s Saïd Business School, attracted a host of leading academics, clinicians and investors to discuss the most exciting commercial opportunities and projects in the field of Therapeutics, Small Molecules and Biologics. The event, which was attended by around 200 people, was organised by the NIHR Oxford BRC, ... Read more

Series B round brings in £35.5mm for Evox

Evox Therapeutics Ltd. (engineered exosomes to enable drug delivery across the blood brain barrier, intracellular delivery of...

Series B round brings in £35.5 mm for Evox

Evox Therapeutics Ltd. (engineered exosomes to enable drug delivery across the blood brain barrier, intracellular delivery of...

Forma Therapeutics, University of Oxford to advance development of DUB inhibitors to treat neurodegenerative diseases

Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.

Forma, U. Oxford collaborate on DUBs for neurodegenerative diseases

Forma Therapeutics Holdings LLC and several units of the University of Oxford are collaborating to identify, validate, and de...

Nitric Oxide conference gets under way in Oxford

Delegates from round the world have descended on Oxford for the 10th international conference of the Nitric Oxide Society, which has got under way. This year, the NIHR oxford Biomedical Research Centre is among the sponsors of the event. The conference, which is being held at the University of Oxford’s Mathematical Institute and lasts until ... Read more

Oxford BioDynamics signs new deal to develop predictive biomarkers for IO therapeutics

The deal with a major US biopharmaceutical company demonstrates value of the range of immuno-oncology biomarker applications recently developed using EpiSwitch platform. EpiSwitch is an industrial platform for The post Oxford BioDynamics signs new deal to develop predictive biomarkers for IO therapeutics appeared first on Compelo Medical Devices.

Oxford University Press and Chinese Antibody Society partner to launch Antibody Therapeutics

Oxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. They review the company’s history and the finances that have been raised since its successful public listing on AIM in 1996. Together, they discuss the challenges...

Amgen Invests $66 Million in Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brou...

Evox raises £35m for exosome therapeutics

Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.

Oxford Firm Launches to Develop Quantum-Era Sensor Technology

Oxford HighQ, a spinout from Oxford University, aims to revolutionise chemical and nanoparticle sensor technology with ‘quantum’ sensors up to 10,000 times more sensitive than current counterparts. Oxford HighQ, a quantum technologies spinout from Oxford University, has launched with £2.1m in seed funding to commercialise components of quantum computing technology developed at th...

Prof Duncan Richards appointed to key new Clinical Therapeutics role

A newly appointed professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) will lead Oxford’s answer to the key global challenge of how to determine quickly which potential new therapies have the properties to become important medicines. Professor Duncan Richards (pictured right), who has been appointed the new Climax ... R...

Oxford woman sheds nearly six stone after diabetes diagnosis – Oxford Mail

Oxford MailOxford woman sheds nearly six stone after diabetes diagnosisOxford MailA DIABETES diagnosis was a wake-up call for one Oxford woman who has now shed nearly six stone. 0 comment. Retired nurse Rachel Griffin, 56, from Greater Leys said she was 'shell-shocked' at receiving the diagnosis last year after a routine blood test.and more

Evox Therapeutics Completes £35.5 Million Series B Financing

OXFORD, England, September 3, 2018 /PRNewswire/ -- Proceeds will advance transformative exosome therapeutics pipeline towards the clinic Continued expansion of world-leading exosome platform for delivery Read more...

Parental controls do not stop teens from seeing pornography, new research finds

(University of Oxford) New research from the Oxford Internet Institute, University of Oxford has found that Internet filtering tools are ineffective and in most cases, were an insignificant factor in whether young people had seen explicit sexual content.

FORMA, University of Oxford collaborate to develop deubiquitinating enzyme inhibitors to treat neuro degenerative diseases

FORMA Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neuro

Oxford Immunotec Announces Launch of the Accutix Brand

Oxford Immunotec Global (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the Accutix brand for its tick-borne disease offering. As quoted in the press release: “Incorporating the feedback of our customers was a key consideration in our selection of a new brand name,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford … Continued The po...

Oxford Impact 2018 workshop

Last month, the NIHR Oxford BRC and the UK Cochrane Collaboration organised the Oxford Impact 2018 workshop, which brought together people from a wide range of fields to “think differently about research impact”. The event sought to tackle one of the central challenges of what has become known as the ‘impact agenda’ in healthcare research: ... Read more

Isis Innovation: How the Oxford Sciences Innovation fund is promoting investment in the Oxfordshire region

Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund comprising six key investors: Invesco Asset Management Limited, IP Group plc, Lansdowne Partners (UK) LLP, Oxford University Endowment Fund, the Wellcome Trust, and Woodford Investment Management LLP.

Oxford researcher gets £1m boost to study immunology of asthma

A University of Oxford researcher has received a £1m grant to expand his research into the immunology of lung diseases, including asthma. Dr Tim Hinks has been awarded a Wellcome Trust Clinical Research Career Development Fellowship. The funding that comes with the award will allow Dr Hinks, who is also supported by the NIHR Oxford ... Read more

Health minister visits Oxford BRC

The Health Minister, Lord O’Shaughnessy, visited the NIHR Oxford BRC on Wednesday 30 May to take a look at the ground-breaking research that is taking place in the fields of cancer and genomics. He was accompanied on the tour by Oxford BRC Director Prof Keith Channon and Head of Research Operations Dr Vasiliki Kiparoglou. Lord O’Shaughnessy ... Read more


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks